ReviewJournal of advanced research2026
The landscape of genitourinary cancer vaccines: clinical advances and future opportunities.
Review in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer vaccines have demonstrated potential as a key immunotherapy strategy based on stimulating immune responses targeting tumor-specific antigens and tumor-associated antigens. Therapeutic cancer vaccines have been proven effective in the treatments of genitourinary cancers, such as Sipuleucel-T (Provenge) and Bacillus Calmette-Guérin (BCG). However, the full fulfillment of these potentials remains an ongoing pursuit. AIM OF THE REVIEW: In this review, we provide a comprehensive overview on vaccines for genitourinary cancers, encompassing bladder, renal, and prostate cancer, addressing their mechanisms and the current status of preclinical/clinical outcomes. The combination strategies based on those cancer vaccines are also summarized, which may provide longer-lasting and more effective treatment. Moreover, we discuss the emerging technologies and future directions for genitourinary cancer vaccines. KEY SCIENTIFIC CONCEPTS OF REVIEW: Through different platforms (peptides, DNA, RNA, dendritic cells, etc.), therapeutic cancer vaccines can provoke or strengthen anti-tumor immunity with the assistance of cytokines, chemokines as well as other adjuvants to therefore prevent the deterioration of cancer and eradicate tumor cells. Only a limited number of therapeutic genitourinary cancer vaccines have received regulatory approval, indicating that there are still many critical challenges for the clinical translation of cancer vaccines, which mainly focus on finding effective antigens, immunogenic platforms and suitable combinational clinical strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.